PeptideStack
5.2kquestions
20kanswers
220users

Is potassium a better monitoring choice than lipase on cagrilintide?

Asked 29 Apr 2025Modified 12 months agoViewed 28k times
17

Details up front: potassium · lipase · cagrilintide.

I am trying to choose between two options that are usually discussed as though only one exists.

I am not optimising for price, but I am not indifferent to it either.

What does each option buy me, and what does it cost me?

bloodwork
bloodwork

Laboratory monitoring: which panels are worth ordering, sensible intervals, reference-range versus optimal-range arguments, and how to read a…

296 questions
kidney-function
kidney-function

eGFR, creatinine, cystatin C and albuminuria: the acute haemodynamic dip that is not injury, the renal outcome data from the FLOW programme, and…

141 questions
lipids
lipids

Lipid response on treatment: triglycerides, LDL-C, non-HDL-C, ApoB and Lp(a), which of them move with weight loss, and why a fasting panel drawn…

139 questions
electrolytes
electrolytes

Sodium, potassium and magnesium during reduced intake and GI losses: what the symptoms of a shortfall look like, when a panel is worth drawing,…

72 questions
pancreatitis
pancreatitis

Acute pancreatitis as a labelled risk: background incidence, the signal in pooled trial and pharmacovigilance data, lipase interpretation, and the…

30 questions
shareeditfollowflag
SF
askedshear_at_the_front17k2729 Apr 2025
8Which analyte, and what reference interval did the laboratory print beside it? – orla_ferriter 6 months ago
add a comment

5 Answers

Accepted answer first, then by votes
142

Accepted answer

Before reacting to any single value, check whether it is outside the interval by an amount larger than the assay's own variation.

A twenty-analyte panel run on a healthy person will produce, on average, one out-of-range result purely from how reference intervals are constructed. That is arithmetic rather than pathology.

Relative to absolute, worked

QuantityValueDerivation
Control-arm event rate8.0 %From the trial table, not the abstract
Hazard ratio0.80Reported
Treated event rate6.4 %8.0 × 0.80
Absolute risk reduction1.6 pp8.0 − 6.4
Number needed to treat631 ÷ 0.016
Relative risk reduction20 %1 − 0.80

The last two rows describe the same finding. Only one of them is used in headlines.

Stated carefully, a sensible core for this population is a full blood count, renal function with electrolytes, liver enzymes with bilirubin, a fasting lipid panel with apolipoprotein B, HbA1c and thyroid-stimulating hormone.

Reference intervals are conventionally the central ninety-five per cent of a reference population, which is the direct cause of the one-in-twenty out-of-range rate on a healthy panel.

The caveat is that a panel is not a diagnosis and interpreting one is a clinician's job, particularly when several values move together.

Baseline first, then a repeat under identical conditions. Everything else is secondary.

edited 18 Jul 2025 by Dr_Marek_Zielinski — reworded for clarity after a comment

shareimprove this answerflag
DZ
answered · acceptedDr_Marek_Zielinski27k276 Jul 2025
7Small correction: eGFR is an estimate derived from creatinine, not a measurement, and the equation used matters. – bac_or_bust 7 months ago
add a comment
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
41

The short version: a small, well-chosen panel with a baseline beats a large one without.

Delta checks — comparing against your own previous value — are far more sensitive than comparing against a population interval, which is the argument for keeping a series rather than a snapshot.

Keep the reports rather than the numbers. Units, reference intervals and methods all vary, and a bare number two years later is not comparable to anything.

Pre-analytical factors — posture, tourniquet time, fasting, sample handling — are the largest source of error in routine biochemistry, well ahead of the analysis itself.

One out-of-range value on a twenty-analyte panel is expected. Two on a repeat is a finding.

shareimprove this answerflag
LS
answeredlow_dead_space37k3714 Jun 2025
34

Specifically, this is answerable, and the answer is mostly about which tests rather than how many.

Same laboratory, same method, same time of day, same fasting state. Between-laboratory differences on several common analytes are larger than the changes people are trying to detect.

Repeat before you react. A single abnormal value has a substantial probability of being within the combined biological and analytical variation of a normal one.

External quality assurance schemes document between-laboratory differences on common analytes that routinely exceed the size of clinically interesting changes.

Keep the full report, not the number. You will need the units and the interval later.

shareimprove this answerflag
CD
answeredcolm_dunphy8.2k143 Jun 2025
2

The honest position is that most people order too many analytes and too few time points, when the reverse would be more informative.

Haemolysis in the sample raises potassium and several enzymes spuriously. If a result is bizarre, ask whether the sample was flagged before building a theory on it.

Ordering tests you will not act on generates anxiety and incidental findings, both of which have costs.

Decide the action for each result before you order the test.

shareimprove this answerflag
DB
answeredDr_Signe_Baldursdottir29k2723 May 2025
1

Answer first: decide what you would do differently for each possible result before you order the panel. Anything that fails that test is a number you will worry about and not act on.

Timing matters per analyte: cortisol and testosterone are diurnal, triglycerides are postprandial, and creatinine responds to hydration and to recent training. Fixing the conditions removes most of the noise.

Nothing here is medical advice. If something is out of range and you do not know why, that is a consultation rather than a research project.

Same laboratory, same time, same fasting state, or the comparison is not a comparison.

shareimprove this answerflag
SL
answeredsian_llewellyn65k14725 Jun 2025
4Adding a vote because this deserves more of them. – a_lindgren 2 months ago
5Delta checks against your own previous value are the part I had not thought about, and it reframes the whole panel. – Dr_Priya_Raghunathan 3 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.